// App-Quantinova.ai

TCT-316 : Impact of Geographic Variation on the Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent: Results From the PIONEER III Clinical Trial in North America, Europe, and Japan

Researchers

Presenter

  • Philippe Garot

Principal Investigators

  • Shigeru Saito

  • Andreas Baumbach

  • Dean Kereiakes

  • Stephan Windecker

  • Cody Pietras

  • Ovidiu Dressler

  • Melek Issever

  • Michael Curtis

  • Barry Bertolet

  • James Zidar

  • Pieter Smits

  • Victor Alfonso Jimenez Diaz

  • Brent McLaurin

  • Angel Cequier

  • Sjoerd Hofma

  • Nabil Dib

  • Akihiko Takahashi

  • Tsunekazu Kakuta

  • Atsushi Hirohata

  • Alexandra Lansky

Medical Centers

  • Cardiovascular Research Foundation, New York, New York, USA

  • North Mississippi Medical Center, Tupelo, Mississippi, USA

  • Yale Cardiovascular Research Group, New Haven, Connecticut, USA

  • The Christ Hospital Heart and Vascular Center, Cincinnati, Ohio, USA

  • The Sakakibara Heart Institute of Okayama, Tsuchiura, Japan

  • Sakurakai Takahashi Hospital, Kobe, Japan

  • University of North Carolina/REX Healthcare, Raleigh, North Carolina

  • Dignity Health, Phoenix, Arizona, USA

  • Foothills Medical Center, Calgary, Alberta, Canada

  • Maasstad Ziekenhuis, Rotterdam, Netherlands

  • Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan

  • Yale School of Medicine, New Haven, Connecticut, USA

  • Bellvitge University Hospital, Barcelona, Spain

  • Medical Center Leeuwarden, Leeuwarden, Netherlands

  • Swiss Cardiovascular Center Bern, Bern, Switzerland

  • Hospital Alvaro Cunqueiro, University Hospital of Vigo, Vigo, Spain

  • AnMed Health, Anderson, South Carolina, USA

  • NewYork–Presbyterian/Columbia University Irving Medical Center, New York, New York, USA

  • Institut Cardiovasculaire Paris-Sud, Ramsay Générale de Santé, Massy, France

  • Barts Heart Centre, London, United Kingdom

Locations

  • United States

  • Japan

  • Spain

  • Netherlands

  • Switzerland

  • Canada

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Diabetes

Biomarkers

  • N/A

Drug/Treatment

  • sirolimus

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved